The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL) and shows poor survival.
This study to evaluate the efficacy and safety of Bortezomib combined with Fludarabine and
Cytarabine treatment in the naive and relapsed MCL who are not eligible for high dose therapy
and transplantation.